A5053039908- Lung Cancer Treatments and Mutations
- Head and Neck Cancer Studies
- Cancer Immunotherapy and Biomarkers
- Thyroid Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Molecular Biology Techniques and Applications
- Cancer-related molecular mechanisms research
- Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- BRCA gene mutations in cancer
- RNA modifications and cancer
- Lung Cancer Diagnosis and Treatment
- Colorectal and Anal Carcinomas
- Nutrition, Genetics, and Disease
- Multiple Myeloma Research and Treatments
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Protein Degradation and Inhibitors
- Cancer Research and Treatments
- Brain Metastases and Treatment
- Peptidase Inhibition and Analysis
- Gastric Cancer Management and Outcomes
- Cell Adhesion Molecules Research
- COVID-19 Clinical Research Studies
- T-cell and B-cell Immunology
Dana-Farber Cancer Institute
2019-2025
Harvard University
2018-2024
Beth Israel Deaconess Medical Center
2018-2024
Brigham and Women's Hospital
2021-2024
Dana-Farber Brigham Cancer Center
2024
Hudson Institute of Medical Research
2024
Lahey Medical Center
2019
Bharati Vidyapeeth Deemed University
2019
Hadassah Medical Center
2019
Advanced Materials Enterprises (China)
2019
<h3>Importance</h3> Despite approximately 40% of patients having Eastern Cooperative Oncology Group (ECOG) performance status (PS) scores at least 2 in the real world, most landmark clinical trials that led to use pembrolizumab as standard care advanced non–small cell lung cancer (NSCLC) excluded this group. <h3>Objective</h3> To evaluate whether an ECOG PS score start therapy is associated with progression-free survival (PFS) and overall (OS) NSCLC treated monotherapy. <h3>Design, Setting,...
Circulating tumor tissue-modified viral (TTMV) human papillomavirus (HPV) DNA is a dynamic, clinically relevant biomarker for HPV-positive oropharyngeal squamous cell carcinoma. Reasons its wide pretreatment interpatient variability are not well understood.To characterize clinicopathologic factors associated with TTMV HPV DNA.This cross-sectional study included patients evaluated carcinoma at Dana-Farber Cancer Institute in Boston, Massachusetts, between December 2019 and January 2022 who...
Primary aldosteronism (PA) has been broadly dichotomized into unilateral and bilateral forms. Adrenal vein sampling (AVS) lateralization indices (LI) ≥2 to 4 are the standard-of-care recommend adrenalectomy for presumed PA. We aimed assess rates characteristics of residual PA after AVS-guided adrenalectomy.
To develop and externally validate a prediction model for severe cisplatin associated acute kidney injury (CP-AKI).
Many patients with locoregionally advanced human papillomavirus-negative head and neck squamous cell carcinoma (HNSCC) relapse. ctDNA has the potential to identify minimal residual disease, but its clinical utility for virus-negative HNSCC is not well understood.
The discovery of molecular subtypes non-small cell lung cancer (NSCLC) with oncogenic driver mutations and translocations/rearrangements has led to successful development targeted therapies improvement in outcomes advanced patients.
Resistance to oncogene-targeted therapies involves discrete drug-tolerant persister cells, originally discovered through in vitro assays. Whether a similar phenomenon limits efficacy of programmed cell death 1 (PD-1) blockade is poorly understood. Here, we performed dynamic single-cell RNA-Seq murine organotypic tumor spheroids undergoing PD-1 blockade, identifying subpopulation immunotherapy cells (IPCs) that resisted CD8+ T cell-mediated killing. These expressed Snai1 and stem antigen...
Background Histological transformation of oncogene-driven lung adenocarcinoma to small cell cancer (SCLC) following treatment with tyrosine kinase inhibitors (TKIs) is a well-described phenomenon. Whether similar may drive acquired resistance immune checkpoint (ICPIs) in non-SCLC (NSCLC) uncertain. Hence, tissue biopsies are not universally recommended at progression NSCLC on ICPIs, unlike TKIs. Case presentation We report case woman her mid-60s 35 pack-years tobacco history and stage IV...
Abstract Background: STK-012 is a first-in-class α/β-IL-2R biased partial agonist designed to drive antitumor activity by selectively stimulating CD25+ antigen activated T cells, while avoiding hallmark IL-2 toxicities sparing pleotropic activation of lymphocytes including NK cells. Methods: STK-012-101 Phase 1a/b study administered subcutaneously in subjects with advanced, relapsed/refractory (r/r) solid tumors. During 1a, are enrolled 3+3 dose escalation as monotherapy (QW or Q3W) +...
Abstract Background There are limited therapeutic options for patients with recurrent/metastatic anaplastic thyroid carcinoma (ATC) and radioiodine refractory (RAIR) differentiated (DTC) to multikinase inhibitors. This multicenter trial evaluated sapanisertib, a next-generation oral kinase inhibitor of mTOR complexes 1/2, in ATC RAIR DTC. Methods A safety run-in phase I was followed by nonrandomized II ATC, an exploratory cohort The primary endpoint the proportion who were without disease...
Abstract Background: Observational studies suggest circulating tumor HPV DNA may facilitate early detection of recurrent HPV-positive oropharynx cancer (OPC). We prospectively investigated whether biomarker-guided surveillance detects recurrence sooner than standard-of-care. Patients and Methods: enrolled patients evaluated for OPC at a single center 11/2020-4/2023 undergoing curative-intent treatment in single-arm cohort study. Pretreatment plasma and/or tissue were tested modified viral...
Abstract Background: Head and neck squamous cell carcinomas (HNSCC) can occur in the oral cavity, pharynx, larynx, paranasal sinuses, nasal cavity. Immune checkpoint inhibitors (ICI) have improved survival multiple cancer types, including recurrent/metastatic (R/M) HNSCC. However, majority of patients with R/M HNSCC did not achieve objective response ICI clinical trials. Although tumor tissue DNA methylation has been proposed as a potential biomarker for response, less is known about blood...
<p>Supplemental Appendix 1. Study protocol.</p>
<div>AbstractPurpose:<p>Treatments after anti–PD-1 therapy for patients with recurrent, metastatic head and neck squamous cell carcinoma (HNSCC) are limited. Blocking PI3K signaling may lead to tumor immunomodulation enhanced taxane sensitivity. This phase 2 trial evaluated dual, selective PI3Kδ/γ inhibition docetaxel in refractory HNSCC.</p>Patients Methods:<p>Patients received duvelisib (25 mg orally twice daily) (75 mg/m<sup>2</sup> IV) every 21 days....
<p>Supplemental Table 1. Overview of the multiplex immunofluorescence panel.</p>
<p>Supplemental Table 7. Correlating pre-treatment tumor immune cell parameters with outcomes (N=18).</p>
<p>Supplemental Table 5. Univariate Hazard ratio and 95% CI for Cox proportional hazard models on overall survival.</p>
<p>Supplemental Table 4. Univariate odds ratio and 95% CI for logistic regression models predictors of response.</p>
<p>Supplemental Table 6. Results of multiplex immunofluorescence profiling on tumor specimens.</p>